Safety and Efficacy of pALG in Conditioning Regimen for HLA-Matched Sibling HSCT in Patients With SAA or Hematological Malignancies ( pALG-MSDHSCT )
Safety and Efficacy of Anti-human T-cell Porcine Immunoglobulin in Conditioning Regimens for HLA Sibling Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Severe Aplastic Anemia (SAA)/Hematological Malignancies
This study is a single-arm clinical study designed to evaluate the safety and efficacy of p-ALG in HLA sibling identical Hematopoietic stem cell transplantation( HSCT) conditioning regimens for severe aplastic anemia (SAA)/hematologic malignancies in patients diagnosed with hematologic malignancies or sSAA requiring allogeneic HSCT from our center. Graft anti-host disease (GVHD) is the most common and severe complication of allogeneic HSCT, which significantly affects survival and quality of life. Even among recipients of HLA-identical sibling HSCT (MSD-HSCT), the incidence of acute GVHD( aGVHD) and chronic GVHD (cGVHD) reaches 40-50% and 30-70%, respectively.
調査の概要
状態
詳細な説明
This study was designed to explore the safety and efficacy of anti-human T cell porcine immunoglobulin p-ALG in the conditioning regimen of HLA sibling allogeneic hematopoietic stem cell transplantation for severe aplastic anemia (SAA)/hematological malignancies in 60 patients.
(1)30 patients with severe aplastic anemia type I and type II underwent MSD-HSCT, p-ALG: 20mg/kg/d for 5 days; (2)30 patients with malignant hematologic diseases, aged over 40 years, either as patients or donors, underwent sibling allogeneic transplantation, with pALG administered at 20mg/kg/d for 3 days.
The enrollment time was 24 months, and patients were followed up for 24 months to evaluate long-term efficacy.
Pharmacokinetics, inflammatory cytokines and active antibodies were measured on day 0 before pALG administration and on days 3, 5, 7, 14, 21, 28 and 60 after p-ALG administration.
Routine follow-up after transplantation was performed to assess implantation and chimerism rate, immune reconstitution, infection prevention, graft versus host disease prevention, treatment-related mortality, and overall survival.
Blood routine, urine routine, liver and kidney function, clinical manifestations and ECOG score were recorded on 28± 7,60 ± 7,90 ± 7,180 ± 7,270 ± 7,360 ± 7,450 ± 7,540 ± 7,630 ± 7,720 ±7 days after transplantation; implantation rate, OS, aGVHD, cGVHD, CMV, EB virus and other infections were recorded.
研究の種類
入学 (推定)
連絡先と場所
研究連絡先
- 名前:Erlie Jiang
- 電話番号:+86-15122538106
- メール:jiangerlie@ihcams.ac.cn
研究連絡先のバックアップ
- 名前:Xin Chen
- 電話番号:+86-13920985705
- メール:chenxin@ihcams.ac.cn
研究場所
-
-
Tianjin Municipality
-
Tianjin、Tianjin Municipality、中国、300020
- National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College Hospital
-
-
参加基準
適格基準
就学可能な年齢
- 子
- 大人
- 高齢者
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
Patients with severe aplastic anemia (type I/II) or hematologic malignancies undergoing HLA-matched sibling hematopoietic stem cell transplantation.
説明
Inclusion Criteria
- age: no age limit for severe aplastic anemia type I or II, patient or donor age>40 years for hematologic malignancies;
- gender: no gender limit;
- sibling identical hematopoietic stem cell transplantation;
- fair general status, ECOG score <2 points;
- no age limit for severe aplastic anemia, no gender limit; patient or donor age>40 years for hematologic malignancies.
Exclusion Criteria:
- uncontrolled viral, bacterial and fungal infections (disease progression during antifungal therapy);
- pregnant and lactating patients or patients unable to use appropriate contraception during treatment;
- psychiatric disorders or other medical conditions unable to comply with study treatment and monitoring requirements;
- known seropositive for HIV, active hepatitis B, active hepatitis C virus, or syphilis;
- history of tumor and treatment for any tumor within the past 3 years;
- Prior hematopoietic stem cell transplantation;
- Active heart disease, defined as one or more of the following: ① Long QTc syndrome or QTc interval>480ms;② Complete left bundle branch block, degree II or III atrioventricular block;③ History of arrhythmia requiring medication or severe clinical symptoms;④ American New York Heart Association classification ≥II; ④ Left ventricular ejection fraction less than 50%; History of myocardial infarction, unstable angina pectoris, severe unstable ventricular arrhythmia or any other arrhythmia requiring treatment, history of clinically serious pericardial disease, or ECG evidence of acute ischemic or active conduction system abnormalities within 6 months prior to enrollment.
- Subjects considered unsuitable for enrollment by the investigator.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 観測モデル:COHORT
- 時間の展望:PROSPECTIVE
コホートと介入
グループ/コホート |
介入・治療 |
|---|---|
|
p-ALG cohort
(1)30 patients with severe aplastic anemia type I and type II underwent MSD-HSCT, p-ALG: 20mg/kg/d for 5 days; (2)30 patients with malignant hematologic diseases, aged over 40 years, either as patients or donors, underwent sibling allogeneic transplantation, with pALG administered at 20mg/kg/d for 3 days. |
(1)30 patients with severe aplastic anemia type I and type II underwent MSD-HSCT, p-ALG: 20mg/kg/d for 5 days; (2)30 patients with malignant hematologic diseases, aged over 40 years, either as patients or donors, underwent sibling allogeneic transplantation, with pALG administered at 20mg/kg/d for 3 days. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Incidence of acute graft-versus-host disease (aGVHD)
時間枠:within 100 days after hematopoietic stem cell infusion
|
aGVHD was evaluated via the modified Glucksberg criteriahematopoietic stem cell transplantation, diagnosed and graded according to standard criteria. |
within 100 days after hematopoietic stem cell infusion
|
|
Incidence of chronic graft-versus-host disease (cGVHD)
時間枠:5 years after hematopoietic stem cell transplantation
|
cGVHD was defined in accordance with the National Institutes of Health (NIH) guidelines |
5 years after hematopoietic stem cell transplantation
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
1-year implantation rate
時間枠:1-year
|
The rate of primary and secondary poor engraftment of neutrophils and platelets within 1 year |
1-year
|
|
Overall survival rate
時間枠:5 years after hematopoietic stem cell transplantation
|
All-cause mortality from hematopoietic stem cell infusion to the last follow-up |
5 years after hematopoietic stem cell transplantation
|
|
Rejection (AA) or recurrence (malignant)
時間枠:5 years after hematopoietic stem cell transplantation
|
Rejection (AA) or recurrence (malignant) from hematopoietic stem cell infusion to the last follow-up |
5 years after hematopoietic stem cell transplantation
|
|
Incidence of fungal infection
時間枠:2 years after hematopoietic stem cell infusion
|
Incidence of fungal infection from hematopoietic stem cell infusion to the last follow-up |
2 years after hematopoietic stem cell infusion
|
|
Incidence of cytomegalovirus infection
時間枠:2 years after hematopoietic stem cell infusion
|
Incidence of cytomegalovirus infection from hematopoietic stem cell infusion to the last follow-up |
2 years after hematopoietic stem cell infusion
|
|
Incidence of Epstein-Barr virus infection
時間枠:2 years after hematopoietic stem cell infusion
|
Incidence of Epstein-Barr virus infection from hematopoietic stem cell infusion to the last follow-up |
2 years after hematopoietic stem cell infusion
|
|
Transplant-related mortality
時間枠:5 years after hematopoietic stem cell infusion
|
Non-relapse/progression-related death occurring within 100 days after hematopoietic stem cell infusion |
5 years after hematopoietic stem cell infusion
|
|
Drug-related toxic and side effects from hematopoietic stem cell infusion to the last
時間枠:2 years after hematopoietic stem cell infusion
|
Drug-related toxic and side effects from hematopoietic stem cell infusion to the last follow-up |
2 years after hematopoietic stem cell infusion
|
協力者と研究者
研究記録日
主要日程の研究
研究開始 (推定)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。